Post

CiMaas files for bankruptcy, aims for restart

To our greatest regret CiMaas has filed for bankruptcy, which became effective Tuesday June 11, 2024. Although CiMaas has great assets in the field of NK cell immunotherapy for cancer using its proprietary feeder cell technology and expansion methodology, it was unable to raise enough financial resources to perform the required clinical studies. 

Post

CiMaas and CYTEA BIO are pleased to announce their collaboration on Natural Killer cells

Under the agreement, CiMaas will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical cord blood-derived NK cells. Conversely, CYTEA BIO will supply CiMaas with Pin™ antibodies for the pre-arming of CiMaas NK cells to assess the benefit it brings and the opportunity to pursue a longer-term partnership.

Post

CiMaas receives EMA qualification for NK cell product

The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell therapy medicinal product with the indication for acute myeloid leukaemia.

Post

EU grants Seal of Excellence to CiMaas

Recently 1085 companies were invited to submit a full proposal – based on a first screening – to apply for an EIC accelerator grant. Of them only 42 were granted (3,8%). A seal of excellence was given to 193 (17,8%), including CiMaas. CiMaas received another opportunity to defend its proposal for the EIC council in… Read more »